Trabectedin

Last updated
Trabectedin
Trabectedin structure.svg
Clinical data
Pronunciation /trəˈbɛktɪdɪn/
trə-BEK-ti-din
Trade names Yondelis
Other namesecteinascidin 743, ET-743
AHFS/Drugs.com Monograph
MedlinePlus a615059
License data
Pregnancy
category
Routes of
administration 		Intravenous
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only) [1]
  • UK: POM (Prescription only) [2]
  • US: ℞-only [3]
  • EU:Rx-only [4]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability Not applicable (IV only)
Protein binding 94 to 98%
Metabolism Liver (mostly CYP3A4-mediated)
Elimination half-life 180 hours (mean)
Excretion Mostly fecal
Identifiers
  • (1'R,6R,6aR,7R,13S,14S,16R)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro[6,16-(epithiopropano-oxymethano)-7,13-imino-6aH-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'(2'H)-isoquinolin]-5-yl acetate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.223.368 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C39H43N3O11S
Molar mass 761.84 g·mol−1
3D model (JSmol)
  • Cc1cc2c(c(c1OC)O)[C@@H]3[C@@H]4[C@H]5c6c(c7c(c(c6OC(=O)C)C)OCO7)[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)c9cc(c(cc9CCN8)O)OC
  • InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1 X mark.svgN
  • Key:PKVRCIRHQMSYJX-AIFWHQITSA-N X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer. [3] [4]

Contents

The most common adverse reactions include nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache. [3] [4]

It is sold by Pharma Mar S.A. and Johnson and Johnson. It is approved for use in the European Union, Russia, South Korea and the United States. The European Commission and the U.S. Food and Drug Administration (FDA) granted orphan drug status to trabectedin for soft-tissue sarcomas and ovarian cancer.

Discovery and production

During the 1950s and 1960s, the National Cancer Institute carried out a wide-ranging program of screening plant and marine organism material. As part of that program, extract from the sea squirt Ecteinascidia turbinata was found to have anticancer activity in 1969. [5] Separation and characterization of the active molecules had to wait many years for the development of sufficiently sensitive techniques, and the structure of one of them, Ecteinascidin 743, was determined by KL Rinehart at the University of Illinois in 1984. [6] Rinehart had collected his sea squirts by scuba diving in the reefs of the West Indies. [7] The biosynthetic pathway responsible for producing the drug has been determined to come from Candidatus Endoecteinascidia frumentensis, a microbial symbiont of the tunicate. [8] The Spanish company PharmaMar licensed the compound from the University of Illinois before 1994[ citation needed ] and attempted to farm the sea squirt with limited success. [7] Yields from the sea squirt are extremely low - 1 tonne of animals is needed to isolate 1 gram of trabectedin - and about 5 grams were believed to be needed for a clinical trial [9] so Rinehart asked the Harvard chemist E. J. Corey to search for a synthetic method of preparation. His group developed such a method and published it in 1996. [10] This was later followed by a simpler and more tractable method which was patented by Harvard and subsequently licensed to PharmaMar. [7] The current[ when? ] supply is based on a semisynthetic process developed by PharmaMar starting from safracin B, an antibiotic obtained by fermentation of the bacterium Pseudomonas fluorescens . [11] PharmaMar entered into an agreement with Johnson & Johnson to market the compound outside Europe.[ citation needed ]

Approvals and indications

Trabectedin was first trialed in humans in 1996.[ citation needed ]

Soft tissue sarcoma

In 2007, the European Commission gave authorization for the marketing of trabectedin, under the trade name Yondelis, "for the treatment of patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents". [12] [4] The European Medicine Agency's evaluating committee, the Committee for Medicinal Products for Human Use (CHMP), observed that trabectedin had not been evaluated in an adequately designed and analyzed randomized controlled trial against current best care, and that the clinical efficacy data were mainly based on patients with liposarcoma and leiomyosarcoma. However, the pivotal study did show a significant difference between two different trabectedin treatment regimens, and due to the rarity of the disease, the CHMP considered that marketing authorization could be granted under exceptional circumstances. [13] As part of the approval PharmaMar agreed to conduct a further trial to identify whether any specific chromosomal translocations could be used to predict responsiveness to trabectedin. [14]

Trabectedin is also approved in South Korea [15] and Russia.[ citation needed ]

In 2015, (after a phase III study comparing trabectedin with dacarbazine [16] ), the US FDA approved trabectedin (Yondelis) for the treatment of liposarcoma and leiomyosarcoma that is either unresectable or has metastasized. Patients must have received prior chemotherapy with an anthracycline. [17]

Ovarian cancer and other

In 2008, the submission was announced of a registration dossier to the European Medicines Agency and the FDA for Yondelis when administered in combination with pegylated liposomal doxorubicin (Doxil, Caelyx) for the treatment of women with relapsed ovarian cancer. In 2011, Johnson & Johnson voluntarily withdrew the submission in the United States following a request by the FDA for an additional phase III study to be done in support of the submission. [18]

Trabectedin is[ when? ] also in phase II trials for prostate, breast, and paediatric cancers. [19]

Structure

Trabectedin is composed of three tetrahydroisoquinoline moieties, eight rings including one 10-membered heterocyclic ring containing a cysteine residue, and seven chiral centers. [20] [21]

Biosynthesis

Proposed scheme for the biosynthesis of trabecteden Trabectedin Biosynthesis.png
Proposed scheme for the biosynthesis of trabecteden

The biosynthesis of trabectedin in Candidatus Endoecteinascidia frumentensis starts with a fatty acid loading onto the acyl-ligase domain of the EtuA3 module. A cysteine and glycine are then loaded as canonical NRPS amino acids. A tyrosine residue is modified by the enzymes EtuH, EtuM1, and EtuM2 to add a hydroxyl at the meta position of the phenol, and adding two methyl groups at the para-hydroxyl and the meta carbon position. This modified tyrosine reacts with the original substrate via a Pictet-Spengler reaction, where the amine group is converted to an imine by deprotonation, then attacks the free aldehyde to form a carbocation that is quenched by electrons from the methyl-phenol ring. This is done in the EtuA2 T-domain. This reaction is done a second time to yield a dimer of modified tyrosine residues that have been further cyclized via Pictet-Spengler reaction, yielding a bicyclic ring moiety. The EtuO and EtuF3 enzymes continue to post-translationally modify the molecule, adding several functional groups and making a sulfide bridge between the original cysteine residue and the beta-carbon of the first tyrosine to form ET-583, ET-597, ET-596, and ET-594 which have been previously isolated. [8] A third O-methylated tyrosine is added and cyclized via Pictet-Spengler to yield the final product. [8]

Total synthesis

The total synthesis by E.J. Corey [10] used this proposed biosynthesis to guide their synthetic strategy. The synthesis uses such reactions as the Mannich reaction, Pictet-Spengler reaction, the Curtius rearrangement, and chiral rhodium-based diphosphine-catalyzed enantioselective hydrogenation. A separate synthetic process also involved the Ugi reaction to assist in the formation of the pentacyclic core. This reaction was unprecedented for using such a one pot multicomponent reaction in the synthesis of such a complex molecule.

Mechanism of action

Recently,[ when? ] it has been shown that trabectedin blocks DNA binding of the oncogenic transcription factor FUS-CHOP and reverses the transcriptional program in myxoid liposarcoma. By reversing the genetic program created by this transcription factor, trabectedin promotes differentiation and reverses the oncogenic phenotype in these cells. [22]

Other than transcriptional interference, the mechanism of action of trabectedin is complex and not completely understood. The compound is known to bind and alkylate DNA at the N2 position of guanine. It is known from in vitro work that this binding occurs in the minor groove, spans approximately three to five base pairs and is most efficient with CGG sequences. Additional favorable binding sequences are TGG, AGC, or GGC. Once bound, this reversible covalent adduct bends DNA toward the major groove, interferes directly with activated transcription, poisons the transcription-coupled nucleotide excision repair complex, promotes degradation of RNA polymerase II, and generates DNA double-strand breaks. [22]

Society and culture

In September 2020, the European Medicines Agency recommended that the use of trabectedin in treating ovarian cancer remain unchanged. [23]

Related Research Articles

Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).

<span class="mw-page-title-main">Gemcitabine</span> Chemical compound

Gemcitabine, sold under the brand name Gemzar, among others, is a chemotherapy medication used to treat cancers. It is used to treat testicular cancer, breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. It is administered by intravenous infusion. It acts against neoplastic growth, and it inhibits the replication of Orthohepevirus A, the causative agent of Hepatitis E, through upregulation of interferon signaling.

<span class="mw-page-title-main">Doxorubicin</span> Chemotherapy medication

Doxorubicin, sold under the brand name Adriamycin among others, is a chemotherapy medication used to treat cancer. This includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. It is often used together with other chemotherapy agents. Doxorubicin is given by injection into a vein.

<span class="mw-page-title-main">Leiomyosarcoma</span> Medical condition

A leiomyosarcoma, also known as LMS, is a rare malignant (cancerous) smooth muscle tumor. The origin of the word is from leio- + myo- + sarcoma which means malignant smooth muscle tumor. The stomach, bladder, uterus, blood vessels, and intestines are examples of hollow organs made up of smooth muscles where LMS can be located, however the uterus or abdomen are the most common sites.

<span class="mw-page-title-main">Melphalan</span> Chemical compound

Melphalan, sold under the brand name Alkeran among others, is a chemotherapy medication used to treat multiple myeloma; malignant lymphoma; lymphoblastic and myeloblastic leukemia; childhood neuroblastoma; ovarian cancer; mammary adenocarcinoma; and uveal melanoma. It is taken by mouth or by injection into a vein.

<span class="mw-page-title-main">Dactinomycin</span> Chemical compound

Dactinomycin, also known as actinomycin D, is a chemotherapy medication used to treat a number of types of cancer. This includes Wilms tumor, rhabdomyosarcoma, Ewing's sarcoma, trophoblastic neoplasm, testicular cancer, and certain types of ovarian cancer. It is given by injection into a vein.

<span class="mw-page-title-main">Didemnin</span> Cyclic molecule found in tunicates

Didemnins are cyclic depsipeptide compounds isolated from a tunicate of the genus Trididemnum that were collected in the Caribbean Sea. They were first isolated in 1978 at the University of Illinois.

<span class="mw-page-title-main">Pertuzumab</span> Pharmaceutical drug

Pertuzumab, sold under the brand name Perjeta, is a monoclonal antibody used in combination with trastuzumab and docetaxel for the treatment of metastatic HER2-positive breast cancer; it also used in the same combination as a neoadjuvant in early HER2-positive breast cancer.

Pazopanib, sold under the brand name Votrient, is an anti-cancer medication marketed worldwide by Novartis. It is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide.

<span class="mw-page-title-main">Eribulin</span> Pharmaceutical drug

Eribulin, sold under the brand name Halaven among others, is an anti-cancer medication used to treat breast cancer and liposarcoma.

<span class="mw-page-title-main">Myxoid liposarcoma</span> Medical condition

A myxoid liposarcoma is a malignant adipose tissue neoplasm of myxoid appearance histologically.

<span class="mw-page-title-main">Rucaparib</span> Chemical compound

Rucaparib, sold under the brand name Rubraca, is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1 (PARP-1). It is taken by mouth.

Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.

<span class="mw-page-title-main">Nintedanib</span> Chemical compound

Nintedanib, sold under the brand names Ofev and Vargatef, is an oral medication used for the treatment of idiopathic pulmonary fibrosis and along with other medications for some types of non-small-cell lung cancer.

<i>Ecteinascidia turbinata</i> Species of sea squirt

Ecteinascidia turbinata, commonly known as the mangrove tunicate, is a species of sea squirt species in the family Perophoridae. It was described to science in 1880 by William Abbott Herdman. The cancer drug trabectedin is isolated from E. turbinata.

<span class="mw-page-title-main">Binimetinib</span> Chemical compound

Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway. Inappropriate activation of the pathway has been shown to occur in many cancers. In June 2018 it was approved by the FDA in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma. In October 2023, it was approved by the FDA for treatment of NSCLC with a BRAF V600E mutation in combination with encorafenib. It was developed by Array Biopharma.

<span class="mw-page-title-main">Abemaciclib</span> Anti-breast cancer medication

Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.

Robert Maki is an American medical oncologist, Professor of Medicine at the Hospital of the University of Pennsylvania, He is a specialist in the management of and translational research regarding sarcoma, the group of connective tissue malignancies that include leiomyosarcoma, gastrointestinal stromal tumor (GIST), liposarcoma, angiosarcoma, Ewing sarcoma, desmoid tumor and many others.

<span class="mw-page-title-main">PharmaMar</span> Spanish pharmaceutical company

PharmaMar is a Spanish pharmaceutical company headquartered in Colmenar Viejo, Madrid, Spain. Founded in 1986 as a subsidiary of Zeltia, it absorbed its parent company and all its subsidiaries in a reverse merger takeover in 2015. The company is a component of the Madrid Stock Exchange General Index (IGBM) and the IBEX 35 since 2020, after being part of the Ibex Small Cap stock market index.

<span class="mw-page-title-main">Lurbinectedin</span> Chemical compound

Lurbinectedin, sold under the brand name Zepzelca, is a medication used for the treatment of small cell lung cancer.

References

  1. 1 2 "Yondelis". Therapeutic Goods Administration (TGA). 3 May 2021. Retrieved 6 September 2021.
  2. ↑ "Yondelis 1 mg powder for concentrate for solution for infusion - Summary of Product Characteristics (SmPC)". (emc). 21 September 2020. Retrieved 30 September 2020.
  3. 1 2 3 "Yondelis- trabectedin injection, powder, lyophilized, for solution". DailyMed. 22 September 2020. Retrieved 30 September 2020.
  4. 1 2 3 4 "Yondelis EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 30 September 2020.
  5. ↑ Lichter W, Wallham LL, Van Der Worf BA, Middle Brook RE, Sigal MM, Weinheimer AJ (August 1972). Worthen LW (ed.). "Food Drugs from the Sea". Proceedings. Marine Tech Soc. 173: 117–127.
  6. ↑ Rinehart KL (January 2000). "Antitumor compounds from tunicates". Medicinal Research Reviews. 20 (1): 1–27. doi:10.1002/(SICI)1098-1128(200001)20:1<1::AID-MED1>3.0.CO;2-A. PMID   10608919. S2CID   25117225.
  7. 1 2 3 Cromie WJ (4 May 2000). "Potent cancer drugs made -- Sea squirts provide recipe". Harvard University Gazette. Archived from the original on 3 June 2006.
  8. 1 2 3 Rath CM, Janto B, Earl J, Ahmed A, Hu FZ, Hiller L, et al. (November 2011). "Meta-omic characterization of the marine invertebrate microbial consortium that produces the chemotherapeutic natural product ET-743". ACS Chemical Biology. 6 (11): 1244–1256. doi:10.1021/cb200244t. PMC   3220770 . PMID   21875091.
  9. ↑ Pain S (14 September 1996). "Hostages of the deep - Prospectors are taking to the seas in search of new and promising chemicals. But the better the drugs turn out to be, the greater the threat to the animals that produce them". New Scientist.
  10. 1 2 Corey EJ, Gin DY, Kania RS (1996). "Enantioselective Total Synthesis of Ecteinascidin 743". Journal of the American Chemical Society. 118 (38): 9202–9203. doi:10.1021/ja962480t.
  11. ↑ Cuevas C, Pérez M, Martín MJ, Chicharro JL, Fernández-Rivas C, Flores M, et al. (August 2000). "Synthesis of ecteinascidin ET-743 and phthalascidin Pt-650 from cyanosafracin B". Organic Letters. 2 (16): 2545–2548. doi:10.1021/ol0062502. PMID   10956543.
  12. ↑ "YONDELIS (trabectedin)" (PDF). Post-Authorization Summary of Positive Opinion. European Medicines Agency. 24 September 2009. Retrieved 12 November 2019.
  13. ↑ "CHMP evaluation" (PDF).
  14. ↑ "PharmaMar website". Archived from the original on September 18, 2008.
  15. ↑ "S.Korea approves Zeltia cancer drug Yondelis". Reuters. 8 May 2008. Retrieved 30 September 2020.
  16. ↑ "Trabectedin Superior to Dacarbazine for Leiomyosarcoma, Liposarcoma". Cancer Network. 21 September 2015. Archived from the original on 5 March 2016.
  17. ↑ "FDA Approves Trabectedin (Yondelis) for Advanced Soft-Tissue Sarcoma". Cancer Network. 26 October 2015. Archived from the original on 17 March 2016.
  18. ↑ Grogan K (3 May 2011). "J&J pulls submission for Zeltia's Yondelis". PharmaTimes Magazine . London, England. Online PharmaTimes. Archived from the original on 2 October 2011. Retrieved 7 May 2011.
  19. ↑ "Yondelis (trabectedin)". PharmaMar. Archived from the original on 13 February 2012.
  20. ↑ D'Incalci M, Galmarini CM (August 2010). "A review of trabectedin (ET-743): a unique mechanism of action". Molecular Cancer Therapeutics. 9 (8): 2157–2163. doi:10.1158/1535-7163.MCT-10-0263. PMID   20647340. S2CID   6723817.
  21. ↑ Chukwueke UN, Wen PY (2020). "Medical management of meningiomas". In McDermott MW (ed.). Meningiomas, Part II. Vol. 170. Elsevier. pp. 291–302. doi:10.1016/B978-0-12-822198-3.00048-3. ISBN   978-0-12-822198-3. PMC   6169485 . PMID   32586501.{{cite book}}: |journal= ignored (help)
  22. 1 2 Grohar PJ, Griffin LB, Yeung C, Chen QR, Pommier Y, Khanna C, et al. (February 2011). "Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells". Neoplasia. 13 (2): 145–153. doi:10.1593/neo.101202. PMC   3033593 . PMID   21403840. and works cited therein.
  23. ↑ "Yondelis". European Medicines Agency (EMA). 27 February 2020. Retrieved 30 September 2020.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.